Secukinumab in psoriasis: Early improvement in patient-reported symptom diary predicts clinical response - 09/05/15
Boni Elewski, MD, University of Alabama at Birmingham, Birmingham, AL, United States; Mark Lebwohl, MD, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Bruce Strober, MD, University of Connecticut Health Center, Farmington, CT, United States; Jacek Szepietowski, MD, Wroclaw Medical University, Wroclaw, Poland; Andrew Blauvelt, MD, MBA, Oregon Medical Research Center, Portland, OR, United States; Joel Schlessinger, MD, Advanced Skin Research Center, Omaha, NE, United States; Judit Nyirady, MD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; Yang Zhao, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; Mary Helen Tran, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; Lori McLeod, PhD, RTI Health Solutions, Research Triangle Park, NC, United States; Dawn Odom, MS, RTI Health Solutions, Research Triangle Park, NC, United States; Alice Gottlieb, MD, Tufts Medical Center, Boston, MA, United States
Le texte complet de cet article est disponible en PDF. Funding by Novartis. |
Vol 72 - N° 5S1
P. AB249 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?